Anbio Biotechnology (NNNN) Stock

About Anbio Biotechnology

Anbio Biotechnology is led by CEO Michael Lau, employs 27 people, headquartered in DE, publicly traded since 2025.

Anbio Biotechnology (NNNN) stock trades at $3.81 with a market capitalization of $167.23M. The stock is valued at a price-to-earnings (P/E) ratio of 32.57, price-to-book of 9.17, price-to-sales of 23.48. Over the past 52 weeks the stock has ranged between $3.13 and $51.33, and currently trades 92.6% below its 52-week high.

On profitability, Anbio Biotechnology generates a return on equity (ROE) of 27.49%, above the typical market range of roughly 12-15%, return on capital employed of 25.46%, an operating margin of 66.47%, a net profit margin of 72.09%.

Anbio Biotechnology by the numbers, 2021–2025

Between 2021 and 2025 Anbio Biotechnology reported revenue of $4.0M rising to $9.0M, a change of +125.0% across 5 years. Compounded, revenue has grown —% a year over five years, -27.9% over three, 12.5% over the last twelve months. Net profit rose to $6.0M.

Operating margin went from 55.5% in 2021 to 66.7% in 2025, a gain of 11.2 percentage points. The most recent net margin is 72.09%. On a trailing twelve-month basis to Dec '25, revenue is $15.0M and net profit $7.0M.

Borrowings stand at $0, cash from operations was $-7.0M in the latest year, positive in 4 of the last 5.

Return on equity has averaged 44.4% over five years, and was 20.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, 278.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Anbio Biotechnology (NNNN) — frequently asked questions